BTX:NSD-Brooklyn ImmunoTherapeutics, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.50

Change

-0.24 (-2.75)%

Market Cap

USD 0.45B

Volume

0.29M

Avg Analyst Target

USD 20.00 (+135.29%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York. Address: Building A, Brooklyn, NY, United States, 11220

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-4.86 (-1.41%)

USD139.56B 40.85 31.63
BNTX BioNTech SE

-13.62 (-4.66%)

USD70.91B 16.26 11.68
REGN Regeneron Pharmaceuticals Inc

-2.55 (-0.43%)

USD62.24B 10.69 7.94
VRTX Vertex Pharmaceuticals Incorpo..

-3.13 (-1.70%)

USD47.75B 24.27 16.15
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-16.37 (-4.27%)

USD35.80B N/A N/A
SGEN Seagen Inc

-3.09 (-1.74%)

USD32.33B 55.44 43.27
GMAB Genmab A/S

-0.46 (-1.01%)

USD30.35B 77.92 9.04
ALNY Alnylam Pharmaceuticals Inc

-6.55 (-3.31%)

USD23.50B N/A N/A
RPRX Royalty Pharma plc

-0.93 (-2.46%)

USD22.91B 30.56 12.22

ETFs Containing BTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 733.33% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 733.33% 99% A+ 99% A+
Trailing 12 Months  
Capital Gain 733.33% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 733.33% 98% A+ 99% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 319.28% 96% A 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 319.28% 96% A 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 727.46% 7% F 1% F
Risk Adjusted Return 43.89% 57% F 48% F
Market Capitalization 0.45B 58% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.32 64% D 90% A-
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -116.11 96% A 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -15,616.18% 1% F 8% F
Return on Invested Capital 0.00% 85% B 52% F
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 62,514.69% 0% N/A 1% F
Technical Ratios  
Short Ratio 1.02 83% B 77% C+
Short Percent 2.33% 73% C 56% F
Beta 3.15 2% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector